Category Archives: Health economics

HEB newsletter

The health economics unit at Bristol University have issued their autumn newsletter. The newsletter features staffing news, new grants and publications and event reports. There are also brief features on projects on the cost-effectiveness of screening for atrial fibrillation, the use of anti-Vascular Endothelial Growth Factor injections to treat eye conditions and the use of think-aloud interviews to determine the appropriate patient reported outcome measure to use with kidney patients.


Public Health England blog post

The Public Health Matters blog from Public Health England features a post from the organisation’s Chief Economist, Brian Ferguson. The post is entitled ‘Making the case for prevention‘ and proposes an economic case for focussing resources on prevention. The post also highlights the Health Economics Evidence Resource (HEER) tool highlighted in a previous post. HEER will be launched at the Public Health England annual conference.

Health economics evidence resource tool

Public Health England have developed a health economic evidence resource (HEER) tool to show the key cost-effectiveness and return on investment evidence on public health activities. The tool is designed to provide an initial ‘snapshot’ of the economic evidence underpinning public health interventions. There are nine areas of public health activity including obesity and physical activity; alcohol misuse; and smoking and tobacco use. Short summaries of the intervention and a link to the original source are included.

Urology Awareness Month

The NIHR highlighted the SUSPEND study as part of Urology Awareness Month. The study was published in the Lancet journal in 2015 and the NIHR news release states that the results of the SUSPEND study have changed practice across most urology departments in the UK and led to changes in the European Association of Urology guidelines for managing ureteric stones. Chris Harding, NIHR Clinical Research Network Sub-Specialty Lead for Benign Urology, said that the “study has changed urology treatment across the UK and internationally”.  HERU were involved in the SUSPEND trial which found that the two drugs in the trial, tamsulosin and nifedipine, were unlikely to be cost-effective in the management of ureteric stones in hospitalised adults.

OHE update on EQ-5D-5L

A blog post from the Office of Health Economics summarises the current situation on the use of the EQ-5D-5L value set, highlights the recent NICE decision and explains and discusses the differences between the EQ-5D-5L and the EQ-5D-3L. It also discusses future research and policy positions.

The published research paper is also available and is discussed in the Academic Health Economists’ Blog.

Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics. 2017;1–16.

OHE paper on eliciting personal utility functions

The Office of Health Economics (OHE) have published a research paper describing a new stated preference technique for directly eliciting personal utility functions. The paper reports the pilot work to test the feasibility and acceptability of the approach for valuing a simplified version of the EQ-5D-5L.

Devlin, N., Shah, K., Mulhern, B., Pantiri, K. and van Hout, B. (2017) A new valuation method: directly eliciting personal utility functions, Research Paper 17/06, London: Office of Health Economics.